A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

NCT04283006 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Relapsed and Refractory
Lymphoid Hematological Malignancies

Interventions

DRUG: CD20/CD22 dual Targeted CAR T-cells

Sponsor

He Huang

Collaborators

[object Object]